At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
06660 AIM VACCINE
Market Closed 03-28 16:08:10
4.210
-0.310
-6.86%
High4.570Low4.150Vol2.16M
Open4.490D1 Closing4.520Amplitude9.29%
Mkt Cap5.17BTradable Cap2.14BTotal Shares1.23B
T/O9.26MT/O Rate0.42%Tradable Shares508.00M
P/B1.38ROE-39.44%EPS-1.15
52wk High15.48052wk Low3.490P/E-3.66
Dividend0.00Div.Yield0.00ROA-14.13%
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
AIM Vaccine FY Gross Margin 74.2%
THOMSON REUTERS  ·  12:57
AIM Vaccine FY Gross Margin 74.2%
AIM Vaccine Co Ltd - FY Loss Attributable RMB277.2 Mln
THOMSON REUTERS  ·  12:57
AIM Vaccine Co Ltd - FY Loss Attributable RMB277.2 Mln
AIM Gets US FDA Clinical Trial Approval for Herpes Zoster Vaccine; Shares Up 8%
MT Newswires Live  ·  03-24
AIM Gets US FDA Clinical Trial Approval for Herpes Zoster Vaccine; Shares Up 8%
BUZZ-China's AIM Vaccine jumps on expectation of narrower annual loss
Reuters  ·  03-17
BUZZ-China's AIM Vaccine jumps on expectation of narrower annual loss
BRIEF-AIM Vaccine Sees FY Unaudited Revenue RMB1.25 Billion To RMB1.3 Billion
Reuters  ·  03-17
BRIEF-AIM Vaccine Sees FY Unaudited Revenue RMB1.25 Billion To RMB1.3 Billion
AIM Vaccine Co Ltd Sees Unaudited Revenue Ranging From RMB1.25 Bln to RMB1.3 Bln for Year
THOMSON REUTERS  ·  03-16
AIM Vaccine Co Ltd Sees Unaudited Revenue Ranging From RMB1.25 Bln to RMB1.3 Bln for Year
AIM Vaccine's Subsidiary's Rabbies Vaccine Clears Phase III, Marketing Registration Application Submitted
MT Newswires Live  ·  03-12
AIM Vaccine's Subsidiary's Rabbies Vaccine Clears Phase III, Marketing Registration Application Submitted
BRIEF-AIM Vaccine's Unit Obtains Production License For Serum-Free Rabies Vaccine
Reuters  ·  03-12
BRIEF-AIM Vaccine's Unit Obtains Production License For Serum-Free Rabies Vaccine
AIM Vaccine Co Ltd - Unit Obtains Production License for Serum-Free Rabies Vaccine
THOMSON REUTERS  ·  03-11
AIM Vaccine Co Ltd - Unit Obtains Production License for Serum-Free Rabies Vaccine
AIM Vaccine's Rabbies Vaccine Gets NMPA Nod for Clinical Trials; Shares Slide 17%
MT Newswires Live  ·  03-10
AIM Vaccine's Rabbies Vaccine Gets NMPA Nod for Clinical Trials; Shares Slide 17%
Private companies are AIM Vaccine Co., Ltd.'s (HKG:6660) biggest owners and were hit after market cap dropped HK$400m
Simply Wall St.  ·  03-03
Private companies are AIM Vaccine Co., Ltd.'s (HKG:6660) biggest owners and were hit after market cap dropped HK$400m
AIM Vaccine Eyes HK$74.7 Million from Share Placement; Shares Slide 12%
MT Newswires Live  ·  02-28
AIM Vaccine Eyes HK$74.7 Million from Share Placement; Shares Slide 12%
BUZZ-China's AIM Vaccine slumps on discounted share sale
Reuters  ·  02-28
BUZZ-China's AIM Vaccine slumps on discounted share sale
BRIEF-Aim Vaccine Co Announces Placing Of 15.5 Million Shares
Reuters  ·  02-28
BRIEF-Aim Vaccine Co Announces Placing Of 15.5 Million Shares
AIM Vaccine Co Ltd - Placing of 15.5 Mln Shares at HK$5.01 per Share
THOMSON REUTERS  ·  02-27
AIM Vaccine Co Ltd - Placing of 15.5 Mln Shares at HK$5.01 per Share
BUZZ-China's AIM jumps on approval of vaccine's clinical trial in US
Reuters  ·  02-27
BUZZ-China's AIM jumps on approval of vaccine's clinical trial in US
AIM Vaccine Gets US FDA Clinical Trial Nod for Respiratory Syncytial Virus Jab
MT Newswires Live  ·  02-27
AIM Vaccine Gets US FDA Clinical Trial Nod for Respiratory Syncytial Virus Jab
BRIEF-AIM Vaccine Says Clinical Trial Of MRNA Respiratory Syncytial Virus Vaccines Approved By FDA
Reuters  ·  02-26
BRIEF-AIM Vaccine Says Clinical Trial Of MRNA Respiratory Syncytial Virus Vaccines Approved By FDA
AIM Vaccine Co Ltd - Clinical Trial of Mrna Respiratory Syncytial- Virus Vaccines Approved by FDA
THOMSON REUTERS  ·  02-26
AIM Vaccine Co Ltd - Clinical Trial of Mrna Respiratory Syncytial- Virus Vaccines Approved by FDA
AIM Vaccine Submits US Clinical Trial Application for Shingles Jab
MT Newswires Live  ·  02-24
AIM Vaccine Submits US Clinical Trial Application for Shingles Jab

Introduction

Company Name.
AIM VACCINE
Affiliated Markets:
SEHK
Listing Date:
2022-10-05
Main Business:
AIM Vaccine Co Ltd is a China-based company mainly engaged in vaccine research and development, manufacturing and sales. The Company's commercialized products mainly include recombinant HBV vaccine, freeze dried human rabies vaccine, inactivated HAV vaccine, mumps vaccine, bivalent inactivated HFRS vaccine and Group A, C, Y and W135 MPSV. The Company's vaccine products under development include 13-Valent Pneumonia Conjugate Vaccine, 24-Valent Pneumonia Conjugate Vaccine, quadrivalent influenza virus vaccine, iterative serum-free rabies vaccine, mRNA shingles/herpes zoster vaccine, Iterative mRNA rabies vaccine, mRNA respiratory syncytial virus vaccine, novel-process highly-effective human diploid rabies vaccine, and others.
Issue price:
16.160
Invest in Global Markets with Tiger Brokers!
Open App